Background/Aims A large percentage of patients undergoing esophagogastroduodenoscopy (EGD) screening do not have esophageal varices (EV) or have only small EV. We evaluated a large, international, multicenter cohort to develop a novel score, termed FIB-4plus, by combining the fibrosis-4 (FIB-4) score, liver stiffness measurement (LSM), and spleen stiffness measurement (SSM) to identify high-risk EV (HRV) in compensated cirrhosis.
Methods This international cohort study involved patients with compensated cirrhosis from 17 Chinese hospitals and one Croatian institution (NCT04546360). Two-dimensional shear wave elastography-derived LSM and SSM values, and components of the FIB-4 score (i.e., age, aspartate aminotransferase, alanine aminotransferase, and platelet count [PLT]) were combined using machine learning algorithms (logistic regression [LR] and extreme gradient boosting [XGBoost]) to develop the LR-FIB-4plus and XGBoost-FIB-4plus models, respectively. Shapley Additive exPlanations method was used to interpret the model predictions.
Results We analyzed data from 502 patients with compensated cirrhosis who underwent EGD screening. The XGBoost-FIB-4plus score demonstrated superior predictive performance for HRV, with an area under the receiver operating characteristic curve (AUROC) of 0.927 (95% confidence interval [CI] 0.897–0.957) in the training cohort (n=268), and 0.919 (95% CI 0.843–0.995) and 0.902 (95% CI 0.820–0.984) in the first (n=118) and second (n=82) external validation cohorts, respectively. Additionally, the XGBoost-FIB-4plus score exhibited high AUROC values for predicting EV across all cohorts. The FIB-4plus score outperformed the individual parameters (LSM, SSM, PLT, and FIB-4).
Conclusions The FIB-4plus score effectively predicted EV and HRV in patients with compensated cirrhosis, providing clinicians with a valuable tool for optimizing patient management and outcomes.
Citations
Citations to this article as recorded by
The evolution of non-invasive strategies in cirrhosis management—from screening to precision monitoring: Editorial on “Fibrosis-4plus score: a novel machine learning-based tool for screening high-risk varices in compensated cirrhosis (CHESS2004): an inter Haiyu Wang, Jinjun Chen Clinical and Molecular Hepatology.2026; 32(1): 403. CrossRef
Metabolic factor-based machine learning model for mortality prediction in acute hepatitis E: Development and validation from a dual-center cohort Haoshuang Fu, Shuying Song, Yuelin Xiao, Bingying Du, Gangde Zhao, Tianhui Zhou, Yanan Du Digestive and Liver Disease.2026; 58(5): 660. CrossRef
Relative change rate of liver stiffness measurements predicts the risk of liver decompensation in compensated advanced chronic liver disease Yanqiu Li, Zihang Qiao, Jinze Li, Bingbing Zhu, Yu Lu, Ying Feng, Xianbo Wang Clinical and Experimental Medicine.2025;[Epub] CrossRef
Artificial Intelligence Applications in the Diagnosis and Management of Cirrhosis and Portal Hypertension: A Narrative Review Amrit Khooblall, Satish E. Viswanath, Layth Khawaja, Sameer Gadani Techniques in Vascular and Interventional Radiology.2025; 28(4): 101078. CrossRef
Liver stiffness measurement-based risk score for predicting liver decompensation risk: a single-center retrospective Chinese study Yanqiu Li, Zihang Qiao, Jinze Li, Yongqi Li, Ying Feng, Xianbo Wang Clinical and Experimental Medicine.2025;[Epub] CrossRef
Metabolomics and metabolites in cancer diagnosis and treatment Minyi Cai, Haiyan Liu, Chen Shao, Tingting Li, Jun Jin, Yahui Liang, Jinhu Wang, Ji Cao, Bo Yang, Qiaojun He, Xuejing Shao, Meidan Ying Molecular Biomedicine.2025;[Epub] CrossRef
Background/Aims Transmembrane 4 L six family member 1 (TM4SF1) is highly expressed and contributes to the progression of various malignancies. However, how it modulates hepatocellular carcinoma (HCC) progression and senescence remains to be elucidated.
Methods TM4SF1 expression in HCC samples was evaluated using immunohistochemistry and flow cytometry. Cellular senescence was assessed through SA-β-gal activity assays and Western blot analysis. TM4SF1-related protein interactions were investigated using immunoprecipitation-mass spectrometry, co-immunoprecipitation, bimolecular fluorescence complementation, and immunofluorescence. Tumor-infiltrating immune cells were analyzed by flow cytometry. The HCC mouse model was established via hydrodynamic tail vein injection.
Results TM4SF1 was highly expressed in human HCC samples and murine models. Knockdown of TM4SF1 suppressed HCC proliferation both in vitro and in vivo, inducing non-secretory senescence through upregulation of p16 and p21. TM4SF1 enhanced the interaction between AKT1 and PDPK1, thereby promoting AKT phosphorylation, which subsequently downregulated p16 and p21. Meanwhile, TM4SF1-mediated AKT phosphorylation enhanced PD-L1 expression while reducing major histocompatibility complex class I level on tumor cells, leading to impaired cytotoxic function of CD8+ T cells and an increased proportion of exhausted CD8+ T cells. In clinical HCC samples, elevated TM4SF1 expression was associated with resistance to anti-PD-1 immunotherapy. Targeting TM4SF1 via adeno-associated virus induced tumor senescence, reduced tumor burden and synergistically enhanced the efficacy of anti-PD-1 therapy.
Conclusions Our results revealed that TM4SF1 regulated tumor cell senescence and immune evasion through the AKT pathway, highlighting its potential as a therapeutic target in HCC, particularly in combination with first-line immunotherapy.
Citations
Citations to this article as recorded by
Multi-omics characterization of RNF157 expression patterns in hepatocellular carcinoma and development of an RNF157-associated prognostic signature Qingsong Yang, Meng Zhang, Chang-song Ma, Ao Li, Wenjun Zhang Frontiers in Pharmacology.2026;[Epub] CrossRef
Progress and challenges in CAR-T cell therapy for bladder cancer Kun Zhao, Zhongze Zhou, Xueming Ma, Xi Xiao, Long Cheng, Shuai Liu, Wenyun Wang, Zhilong Dong Critical Reviews in Oncology/Hematology.2026; 222: 105275. CrossRef
Overcoming immune resistance in hepatocellular carcinoma: insights into mechanisms, predictive factors, and interventional strategies Zhenxao Wang, Jun Wu, Qiao Li, Xin Wen Frontiers in Immunology.2026;[Epub] CrossRef
Resistance to immune checkpoint inhibitors in hepatocellular carcinoma: mechanisms and combination strategies to overcome it Tingjiang He, Ludan Zhang, Qianwei Zhao Hepatoma Research.2026;[Epub] CrossRef
Mechanistic insights into Tuoli Xiaozheng Formula for hepatocellular carcinoma: An integrated network pharmacology, molecular docking, and Mendelian randomization analysis Jianhua Liang, Mengqing Yang, Lijing Xu, Zexian Shi, Youwei Zhou, Junyang Liao, Shidong He, Jieyun Xie Medicine.2026; 105(25): e49422. CrossRef
Glutathione metabolism-linked ferroptosis in human seminoma: a spatial multi-omics mapping study Chenyao Deng, Jiaxing Li, Zhongkai Guo, Jun Zhu, Qiancheng Zhao, Zishui Fang, Jiachen Zheng, Lingxiang Ran, Ruiyu Li, Xuesong Li, Kan Gong, Jing Peng, Aixiang Wang, Jingtao Guo, Yuzhuo Yang, Hui Jiang, Zirun Jin Redox Biology.2026; 95: 104284. CrossRef
TM4SF1 is a surface marker of senescent pancreatic β-cells Ana Beathriz Leite Lorente, Sergio Vazquez, Kanako Iwasaki, Adedoyin Adebayo, Maya Jackson, Christopher Cahill, Summer Ryan, Brooke A. Sullivan, Susan Bonner-Weir, Cristina Aguayo-Mazzucato Aging.2026; 18(1): 815. CrossRef
Regulation of cellular senescence in tumor progression and therapeutic targeting: mechanisms and pathways Bowei Liu, Zhigang Peng, Hao Zhang, Nan Zhang, Zaoqu Liu, Zhiwei Xia, Shaorong Huang, Peng Luo, Quan Cheng Molecular Cancer.2025;[Epub] CrossRef
TM4SF1 - A new immune target for treatment of hepatocellular carcinoma: Editorial on “Targeting TM4SF1 promotes tumor senescence enhancing CD8+ T cell cytotoxic function in hepatocellular carcinoma” Chen Rui Yuan, Terence Kin Wah Lee Clinical and Molecular Hepatology.2025; 31(2): 646. CrossRef
Targeting TM4SF1 to overcome immunotherapy resistance in hepatocellular carcinoma: Editorial on “Targeting TM4SF1 promotes tumor senescence enhancing CD8+ T cell cytotoxic function in hepatocellular carcinoma” Valerie Chew Clinical and Molecular Hepatology.2025; 31(2): 642. CrossRef
Correspondence to editorial on “Targeting TM4SF1 promotes tumor senescence enhancing CD8+ T cell cytotoxic function in hepatocellular carcinoma” Weifeng Zeng, Furong Liu, Yachong Liu, Zhanguo Zhang Clinical and Molecular Hepatology.2025; 31(2): e197. CrossRef
Tetraspan(in)-mediated immune regulation in hepatocellular carcinoma: Editorial on “Targeting TM4SF1 promotes tumor senescence enhancing CD8+ T cell cytotoxic function in hepatocellular carcinoma” Seo Hee Jin, Dong Joo Kim, Jung Weon Lee Clinical and Molecular Hepatology.2025; 31(2): 650. CrossRef
Differential Infiltration of T-Cell Populations in Tumor and Liver Tissues Predicts Recurrence-Free Survival in Surgically Resected Hepatocellular Carcinoma Eun Ji Jang, Ho Joong Choi, Young Kyoung You, Deok Hwa Seo, Mi Hyun Kwon, Keungmo Yang, Jaejun Lee, Jeong Won Jang, Seung Kew Yoon, Ji Won Han, Pil Soo Sung Cancers.2025; 17(9): 1548. CrossRef
Immunoregulatory mechanisms in the aging microenvironment: Targeting the senescence-associated secretory phenotype for cancer immunotherapy Haojun Wang, Yang Yu, Runze Li, Huiru Zhang, Zhe-sheng Chen, Changgang Sun, Jing Zhuang Acta Pharmaceutica Sinica B.2025; 15(9): 4476. CrossRef
Targeting tumor-associated macrophages to overcome immune checkpoint inhibitor resistance in hepatocellular carcinoma Fen Liu, Xianying Li, Yiming Zhang, Shan Ge, Zhan Shi, Qingbin Liu, Shulong Jiang Journal of Experimental & Clinical Cancer Research.2025;[Epub] CrossRef
The role of PD‑1/PD‑L1 axis in liver diseases Zijian Zeng, Shuanglan Chen, Qun Niu, Haijian Dong, Yuanqian Yao, Kaixin Wang, Xueqing Gong, Hui Li Clinical and Experimental Medicine.2025;[Epub] CrossRef
Background/Aims Metabolic dysfunction-associated steatohepatitis (MASH) is a significant risk factor for gallstone formation, but mechanisms underlying MASH-related gallstone formation remain unclear. Golgi membrane protein 1 (GOLM1) participates in hepatic cholesterol metabolism and is upregulated in MASH. Here, we aimed to explore the role of GOLM1 in MASH-related gallstone formation.
Methods The UK Biobank cohort was used for etiological analysis. GOLM1 knockout (GOLM1-/-) and wild-type (WT) mice were fed with a high-fat diet (HFD). Livers were excised for histology and immunohistochemistry analysis. Gallbladders were collected to calculate incidence of cholesterol gallstones (CGSs). Biles were collected for biliary lipid analysis. HepG2 cells were used to explore underlying mechanisms. Human liver samples were used for clinical validation.
Results MASH patients had a greater risk of cholelithiasis. All HFD-fed mice developed MASH, and the incidence of gallstones was 16.7% and 75.0% in GOLM1-/- and WT mice, respectively. GOLM1-/- decreased biliary cholesterol concentration and output. In vivo and in vitro assays confirmed that GOLM1 facilitated cholesterol efflux through upregulating ATP binding cassette transporter subfamily G member 5 (ABCG5). Mechanistically, GOLM1 translocated into nucleus to promote osteopontin (OPN) transcription, thus stimulating ABCG5-mediated cholesterol efflux. Moreover, GOLM1 was upregulated by interleukin-1β (IL-1β) in a dose-dependent manner. Finally, we confirmed that IL-1β, GOLM1, OPN, and ABCG5 were enhanced in livers of MASH patients with CGSs.
Conclusions In MASH livers, upregulation of GOLM1 by IL-1β increases ABCG5-mediated cholesterol efflux in an OPN-dependent manner, promoting CGS formation. GOLM1 has the potential to be a molecular hub interconnecting MASH and CGSs.
Citations
Citations to this article as recorded by
Methylation changes of gallbladder DNA during the formation of gallstones Hongyu Xu, Jinlong Hu, Jinshan Liu, Rui Wang, Junbin Peng, Peilin Liu, Jiaming Yao, Baoqiang Cao Epigenomics.2026; 18(1): 55. CrossRef
Biliary elimination of cholesterol can be modulated by hepatocyte mitochondrial Aquaporin-8 in mice María Celeste Capitani, Alejo M. Capiglioni, Raúl A. Marinelli, Julieta Marrone Scientific Reports.2026;[Epub] CrossRef
Anti-Obesity Effects of Pear Extract (Pyrus pyrifolia): Clinical Implications and Therapeutic Potential Yong Kyun Roh, Yoon-su Ha, Taek-kyong Kim, Kyungseok Kim, Soo Ro Kim, Da Hee Kim, Seonghwan Hwang, Se-Ran Yang, Sunbok Jang, Seung-Jin Kim International Journal of Stem Cells.2026; 19(2): 242. CrossRef
Integrated multi-omics profiling identifies genetic loci of African swine fever resistance in pigs Xiaowei Ye, Qinqin Xie, Caiyun Cao, Shuang Liu, Wenbo Sun, Zhe Zhang, Qishan Wang, Yuchun Pan, Zhen Wang GigaScience.2026;[Epub] CrossRef
Integrating bioinformatics and machine learning to analyze molecular biomarkers, immune infiltration mechanisms, and small-molecule therapeutic candidates for gallstones Zhixing Wei, Yuting Pang, Yun Qiao, Zhigang Wei Letters in Drug Design & Discovery.2026; : 100394. CrossRef
Association of arm circumference with the prevalence of gallstones in United States adults: a retrospective analysis on US National Health and Nutrition Examination Survey Jianjun Wang, Xi Chen, Wei He, Xintao Zeng, Pei Yang, Jianping Gong, Decai Wang Frontiers in Medicine.2025;[Epub] CrossRef
Reply to correspondence 2 on “GOLM1 promotes cholesterol gallstone formation via ABCG5-mediated cholesterol efflux in MASH livers” Nahee Hwang, Sungsoon Fang Clinical and Molecular Hepatology.2025; 31(2): e228. CrossRef
Unraveling the role of GOLM1-OPN-ABCG5 axis in MASH: Editorial on “GOLM1 promotes cholesterol gallstone formation via ABCG5-mediated cholesterol efflux in MASH livers” Yoon-su Ha, Won Kim, Seung-Jin Kim Clinical and Molecular Hepatology.2025; 31(2): 628. CrossRef
Bridging the gap: The GOLM1-OPN-ABCG5 axis in MASH and gallstone disease: Editorial on “GOLM1 promotes cholesterol gallstone formation via ABCG5-mediated cholesterol efflux in MASH livers” Nahee Hwang, Sungsoon Fang Clinical and Molecular Hepatology.2025; 31(2): 631. CrossRef
Correspondence to editorial on “GOLM1 promotes cholesterol gallstone formation via ABCG5-mediated cholesterol efflux in MASH livers” Yi-Tong Li, Wei-Qing Shao, Zhen-Mei Chen, Jing Lin, Jin-Hong Chen Clinical and Molecular Hepatology.2025; 31(2): e186. CrossRef
GOLM1 and bile acid synthesis: Correspondence to editorial on “GOLM1 promotes cholesterol gallstone formation via ABCG5-mediated cholesterol efflux in MASH livers” Yi-Tong Li, Wei-Qing Shao, Zhen-Mei Chen, Jing Lin, Jin-Hong Chen Clinical and Molecular Hepatology.2025; 31(2): e189. CrossRef
Reply to correspondence 1 on “GOLM1 promotes cholesterol gallstone formation via ABCG5-mediated cholesterol efflux in MASH livers” Yoon-su Ha, Won Kim, Seung-Jin Kim Clinical and Molecular Hepatology.2025; 31(2): e226. CrossRef
Pharmacological effects and prospects of traditional Chinese medicine and its bioactive components in the prevention and treatment of urolithiasis and cholelithiasis Dan Jiang, Xiaofeng Zhou, Xiaolong Lu Letters in Drug Design & Discovery.2025; 22(12): 100274. CrossRef
First
Prev
